Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hyperfine, Inc.HYPR · Entity 6865 | Chief Operating Officer | February 09, 2022 | February 11, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hyperfine, Inc.
Report date February 09, 2022 · Filed February 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.90 · Expires 2032-02-09 | Direct | 45,000 |
Reported balance
After 2022-02-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-09 · Grant · Acquired 45,000 · Balance 45,000 F1: The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Mr. Hughes's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Mr. Hughes's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2022 Filed Feb 11, 2022 19:14 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001104659-22-020800 · tm226447-1_4seq1.xml · derivative · entry 1 Hughes Mark A. · CIK 0001898765 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Stock · 45,000 shares Expires 2032-02-09 F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 9, 2023, and 2.083% at the end of each month thereafter beginning on March 31, 2023, subject to Mr. Hughes's continued service through the applicable vesting date. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:46 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantStock Option (right to buy) · Derivative | 60,587 | Not disclosed Strike: $3.27 | Not disclosed |
DisclosureSEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · derivative · entry 6 Hughes Mark A. · CIK 0001898765 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,587 Underlying: Class A Common Stock · 60,587 shares Expires 2031-04-14 F12 · price: Received in connection with the Mergers in exchange for a stock option to acquire 185,000 shares of Hyperfine common stock for $1.07 per share. F11 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments beginning on October 31, 2020, subject to Mr. Hughes's continued service through the applicable vesting date. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:46 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantStock Option (right to buy) · Derivative | 4,912 | Not disclosed Strike: $3.27 | Not disclosed |
DisclosureSEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · derivative · entry 5 Hughes Mark A. · CIK 0001898765 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,912 Underlying: Class A Common Stock · 4,912 shares Expires 2031-04-14 F10 · price: Received in connection with the Mergers in exchange for a stock option to acquire 15,000 shares of Hyperfine common stock for $1.07 per share. F9 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments beginning on October 31, 2020, subject to Mr. Hughes's continued service through the applicable vesting date. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:46 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantStock Option (right to buy) · Derivative | 3,275 | Not disclosed Strike: $3.76 | Not disclosed |
DisclosureSEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · derivative · entry 4 Hughes Mark A. · CIK 0001898765 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,275 Underlying: Class A Common Stock · 3,275 shares Expires 2030-01-18 F8 · price: Received in connection with the Mergers in exchange for a stock option to acquire 10,000 shares of Hyperfine common stock for $1.23 per share. F7 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 31, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:46 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantStock Option (right to buy) · Derivative | 54,037 | Not disclosed Strike: $3.76 | Not disclosed |
DisclosureSEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · derivative · entry 3 Hughes Mark A. · CIK 0001898765 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,037 Underlying: Class A Common Stock · 54,037 shares Expires 2030-01-18 F6 · price: Received in connection with the Mergers in exchange for a stock option to acquire 165,000 shares of Hyperfine common stock for $1.23 per share. F5 · derivative.exercise_date: The shares underlying this option vest as to 25% on December 31, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:46 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantStock Option (right to buy) · Derivative | 21,322 | Not disclosed Strike: $3.76 | Not disclosed |
DisclosureSEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · derivative · entry 2 Hughes Mark A. · CIK 0001898765 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,322 Underlying: Class A Common Stock · 21,322 shares Expires 2029-07-01 F4 · price: Received in connection with the Mergers in exchange for a stock option to acquire 65,106 shares of Hyperfine common stock for $1.23 per share. F3 · derivative.exercise_date: The shares underlying this option vest as to 25% on September 30, 2020, with the remainder vesting in equal monthly installments, over the following three years, subject to Mr. Hughes's continued service through the applicable vesting date. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 21:46 UTC | Hyperfine, Inc. HYPR · Entity 6865 | GrantClass A Common Stock | 19,615 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-153339 · tm2135698-22_4seq1.xml · nonDerivative · entry 1 Hughes Mark A. · CIK 0001898765 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,615 F1 · price: In connection with the closing of the transactions contemplated by the Business Combination Agreement, dated as of July 7, 2021, by and among HealthCor Catalio Acquisition Corp. ("HealthCor"), Optimus Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub I"), Optimus Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of HealthCor ("Merger Sub II"), Hyperfine, Inc., F2 · price: a Delaware corporation ("Hyperfine"), and Liminal Sciences, Inc., a Delaware corporation ("Liminal"), pursuant to which Merger Sub I merged with and into Hyperfine (the "Hyperfine Merger"), with Hyperfine surviving the Hyperfine Merger as a wholly owned subsidiary of HealthCor, and Merger Sub II merged with and into Liminal (the "Liminal Merger" and, together with the Hyperfine Merger, the "Mergers"), with Liminal surviving the Liminal Merger as a wholly owned subsidiary of HealthCor (which changed its name to "Hyperfine, Inc.", the "Issuer"), these shares were received in exchange for 59,894 shares of Hyperfine common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.